{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 307,
  "pageCount": 366,
  "prevPage": 306,
  "nextPage": 308,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a combination of narrative argument and direct excerpts from regulatory documents to highlight a discrepancy in drug efficacy claims.",
  "elementsJson": [
    "paragraph",
    "screenshot",
    "data_table"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/307",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-307",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.07,
        "y": 0.43
      },
      "kind": "callout",
      "text": "Wakix package insert claims 90% bioavailability",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26d19539-58fe-4f5e-a51b-fa6ac0471af9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.58
      },
      "kind": "callout",
      "text": "FDA CDER Tertiary Pharmacology/Toxicological Review – 85%/37% bioavailability in rodents",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77a2a8a3-205c-4e47-95e3-557dbc842af5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "We believe Harmony is aware of pitolisant’s bioavailability problem and that their claim of 90% oral bioavailability/absorption in the package insert is simply false.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d1-73a9-abbc-e42802a2a2f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "bioavailability: 90%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-64d1-73a9-abbc-ed7abbeac5a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "An inability to increase histamine levels and histamine’s irrelevance to narcolepsy and sleepiness are the least of the problems with pitolisant’s purported mechanism of action. A more fundamental issue is its lack of bioavailability...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ff1ab0d-ac40-4cc7-a3d5-cf6af26b61b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.07,
        "y": 0.51
      },
      "kind": "paragraph",
      "text": "The oral absorption of WAKIX is around 90%.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f57efdbc-2851-4563-9a3d-c22808050ad3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "The oral absorption of WAKIX is around 90%. — Wakix package insert",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d1-73a9-abbc-e9c18edc387f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Source: https://www.wakix.com/assets/pdf/WAKIX__pitolisant__tablets_PI_Dec_2022.pdf; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000PharmR.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "034f5e5f-e449-4d1c-acc1-9c10cd8d9f69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.07,
        "y": 0.63
      },
      "kind": "table",
      "text": "Table 8. Serum Concentrations and Bioavailability of Oral and IV Pitolisant in Mice and Rats",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61a24612-dfec-43ba-bfd9-5dac60d6d671",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "f8c719f3-a429-4d87-880c-dc73ada87dcc",
      "evidence": "The slide explicitly identifies a contradiction between company claims and regulatory data to suggest misleading information.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}